Clinical Trial Update: A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating TOMUDEX (raltitrexed) in combination with radiotherapy for patients with inoperable or recurrent rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Tomudex (ZD1694)

Snippet

Sponsor: AstraZeneca | Conditions: Inoperable or Recurrent Rectal Cancer | Phase 2 | Status: COMPLETED